DE602004027824D1 - Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer - Google Patents
Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmerInfo
- Publication number
- DE602004027824D1 DE602004027824D1 DE602004027824T DE602004027824T DE602004027824D1 DE 602004027824 D1 DE602004027824 D1 DE 602004027824D1 DE 602004027824 T DE602004027824 T DE 602004027824T DE 602004027824 T DE602004027824 T DE 602004027824T DE 602004027824 D1 DE602004027824 D1 DE 602004027824D1
- Authority
- DE
- Germany
- Prior art keywords
- topoisomerase
- hemmer
- deacetylase inhibitor
- histon deacetylase
- antitumoral agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940122964 Deacetylase inhibitor Drugs 0.000 title 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 title 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 abstract 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 abstract 1
- 229960002550 amrubicin Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003334340 | 2003-09-25 | ||
JP2003344315 | 2003-10-02 | ||
PCT/JP2004/014451 WO2005030239A2 (en) | 2003-09-25 | 2004-09-24 | Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004027824D1 true DE602004027824D1 (de) | 2010-08-05 |
Family
ID=34380371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004027824T Active DE602004027824D1 (de) | 2003-09-25 | 2004-09-24 | Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer |
Country Status (14)
Country | Link |
---|---|
US (1) | US7314862B2 (de) |
EP (2) | EP1670514B1 (de) |
JP (1) | JP4779971B2 (de) |
AT (1) | ATE471740T1 (de) |
CA (1) | CA2540108A1 (de) |
CY (1) | CY1114359T1 (de) |
DE (1) | DE602004027824D1 (de) |
DK (1) | DK2263694T3 (de) |
ES (2) | ES2344899T3 (de) |
MX (1) | MXPA06003222A (de) |
PL (2) | PL2263694T3 (de) |
PT (1) | PT2263694E (de) |
SI (1) | SI2263694T1 (de) |
WO (1) | WO2005030239A2 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4238728B2 (ja) * | 2001-08-21 | 2009-03-18 | アステラス製薬株式会社 | ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法 |
US8673888B2 (en) * | 2002-04-05 | 2014-03-18 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Depsipeptide for therapy of kidney cancer |
CN1777675A (zh) * | 2003-02-19 | 2006-05-24 | 安斯泰来制药有限公司 | 预测组蛋白去乙酰化酶抑制剂抗肿瘤效果的方法 |
JP2006520796A (ja) * | 2003-03-17 | 2006-09-14 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼインヒビター |
EP1670514B1 (de) | 2003-09-25 | 2010-06-23 | Astellas Pharma Inc. | Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer |
US20050159470A1 (en) * | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
WO2005066151A2 (en) * | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
US7642275B2 (en) * | 2004-12-16 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
JP2008540574A (ja) * | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
BRPI0613429A2 (pt) * | 2005-07-14 | 2009-02-10 | Takeda San Diego Inc | inibidores de histona desacetilase |
WO2007040522A1 (en) * | 2005-09-30 | 2007-04-12 | The Ohio State Research Foundation | Antitumor agents |
JP2009519224A (ja) * | 2005-11-18 | 2009-05-14 | グロスター ファーマシューティカルズ, インコーポレイテッド | Hdacインヒビターfk228の代謝産物誘導体 |
EP1976835A2 (de) * | 2006-01-13 | 2008-10-08 | Takeda San Diego, Inc. | Histondeacetylase-inhibitoren |
WO2008013589A2 (en) * | 2006-04-24 | 2008-01-31 | Gloucester Pharmaceuticals | Treatment of ras-expressing tumors |
WO2007146730A2 (en) | 2006-06-08 | 2007-12-21 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
WO2008082856A1 (en) | 2006-12-26 | 2008-07-10 | Pharmacyclics, Inc. | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
CN103497238A (zh) * | 2006-12-29 | 2014-01-08 | 细胞基因公司 | 制备Romidepsin |
EP2102230A2 (de) | 2006-12-29 | 2009-09-23 | Gloucester Pharmaceuticals, Inc. | Reinigung von romidepsin |
WO2009002941A1 (en) * | 2007-06-22 | 2008-12-31 | Board Of Regents, The University Of Texas System | Composition and method for the treatment of diseases affected by histone deacetylase inhibitors |
US20110021517A1 (en) * | 2008-02-26 | 2011-01-27 | Nerviano Medical Sciences S.R.L. | Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents |
NZ706052A (en) | 2010-07-12 | 2016-07-29 | Celgene Corp | Romidepsin solid forms and uses thereof |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
EP2755648B1 (de) | 2011-09-13 | 2017-03-08 | Pharmacyclics LLC | Formulierungen des histondeacetylase-inhibitors in kombination mit bendamustin und verwendungen davon |
AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
US20150283159A1 (en) * | 2012-11-01 | 2015-10-08 | Microbial Chemistry Research Foundation | Anticancer agent, and combination use anticancer agent |
AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
CN116327887B (zh) * | 2023-04-24 | 2023-11-03 | 南京捷因诊断技术有限公司 | 一种lsd1抑制剂作为抗肿瘤药物的应用 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US574455A (en) * | 1897-01-05 | Switch-lock | ||
US486379A (en) * | 1892-11-15 | Hame-tug | ||
US3997633A (en) * | 1975-06-24 | 1976-12-14 | Max Leva | Contact towers with leak-proof support of improved plate subassembly |
US4315851A (en) * | 1978-12-29 | 1982-02-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Pharmaceutical composition having antitumor activity |
US4348388A (en) * | 1980-04-02 | 1982-09-07 | G.D. Searle & Co. | 11-Amino-11-deoxydaunorubicin and analogs |
GB8426672D0 (en) * | 1984-10-22 | 1984-11-28 | Erba Farmitalia | Pharmaceutical compositions |
US4950755A (en) * | 1985-08-12 | 1990-08-21 | Ohio State University | Bis(morpholinomethyl) derivative of 1,2-bis(dioxopiperizinyl)propane |
US5242901A (en) * | 1988-01-27 | 1993-09-07 | New York University | Reduction of anthracycline induced cardiotoxicity |
GB8817743D0 (en) | 1988-07-26 | 1988-09-01 | Fujisawa Pharmaceutical Co | Fr901228 substance & preparation thereof |
US5514664A (en) * | 1990-05-26 | 1996-05-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh | 1,4-dihydropyridines for application in combatting resistance to drugs |
US5620961A (en) * | 1994-04-25 | 1997-04-15 | Markovic; Nenad S. | Fructose ester-β-cyclodextrin complexes and processes for making and using same |
US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
US6020373A (en) * | 1995-10-20 | 2000-02-01 | Eastern Virginia Medical School | Chelate derivatives as protectors against tissue injury |
US5780054A (en) * | 1996-01-17 | 1998-07-14 | University Of British Columbia | Methods for increasing the circulation half-life of protein-based therapeutics |
US6451784B1 (en) * | 1996-12-30 | 2002-09-17 | Battellepharma, Inc. | Formulation and method for treating neoplasms by inhalation |
JP2001513078A (ja) * | 1996-12-30 | 2001-08-28 | バテル・メモリアル・インスティテュート | 吸入により新生物を治療する製剤とその方法 |
US7229841B2 (en) * | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
US6286513B1 (en) * | 1998-10-22 | 2001-09-11 | Jessie L. Au | Methods for treating superficial bladder carcinoma |
US6197809B1 (en) * | 1998-12-23 | 2001-03-06 | Ardenia Investments Ltd. | Compounds for the treatment of cancer |
US20030144570A1 (en) * | 1999-11-12 | 2003-07-31 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors |
KR101026205B1 (ko) * | 1999-11-23 | 2011-03-31 | 메틸진 인코포레이티드 | 히스톤 디아세틸라제의 억제제 |
US6593308B2 (en) * | 1999-12-03 | 2003-07-15 | The Regents Of The University Of California | Targeted drug delivery with a hyaluronan ligand |
ES2347284T3 (es) | 1999-12-08 | 2010-10-27 | Cyclacel Pharmaceuticals, Inc. | Uso de depsipeptido y congeneres del mismo como inmunosupresores en la prevencion o tratamiento del rechazo que sigue a un transplante y para inducir la apoptosis de celulas t cd4 o cd8 activadas. |
US20020028237A1 (en) * | 2000-04-20 | 2002-03-07 | Colbern Gail T. | Method for reducing toxicity of a cytotoxic agent |
JP4810784B2 (ja) | 2000-07-17 | 2011-11-09 | アステラス製薬株式会社 | 還元型fk228およびその用途 |
CZ2003837A3 (cs) * | 2000-09-22 | 2004-12-15 | Bristol-Myers Squibb Company | Způsob pro snížení toxicity při kombinovaných chemoterapiích |
WO2002024178A2 (en) * | 2000-09-22 | 2002-03-28 | Bristol-Myers Squibb Company | Method for reducing toxicity of combined chemotherapies |
US20020156023A1 (en) * | 2000-12-06 | 2002-10-24 | Tularik Inc. | Lometrexol combination therapy |
WO2002059375A2 (en) * | 2001-01-26 | 2002-08-01 | University Of Chicago | Determination of ugt2b7 gene polymorphisms for predicting ugt2b7 substrate toxicity and for optimising drug dosage |
JP4391087B2 (ja) * | 2001-03-23 | 2009-12-24 | シャイアー カナダ インコーポレイテッド | 癌の処置のための薬学的組み合わせ |
US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
JP4238728B2 (ja) * | 2001-08-21 | 2009-03-18 | アステラス製薬株式会社 | ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法 |
US8673888B2 (en) * | 2002-04-05 | 2014-03-18 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Depsipeptide for therapy of kidney cancer |
CN1652845A (zh) * | 2002-05-17 | 2005-08-10 | 安万特医药股份有限公司 | 多西他赛/阿霉素/环磷酰胺在辅助治疗乳腺癌和卵巢癌中的用途 |
WO2004034876A2 (en) * | 2002-10-15 | 2004-04-29 | Ferx Incorporated | Magnetically guided particles for radiative therapies |
US20040152632A1 (en) * | 2002-11-06 | 2004-08-05 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
US20050222013A1 (en) * | 2003-01-16 | 2005-10-06 | Georgetown University | Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy |
CN1791396A (zh) | 2003-05-21 | 2006-06-21 | 诺瓦提斯公司 | 组蛋白脱乙酰基酶抑制剂与化疗剂的组合 |
PE20050206A1 (es) | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
DK2238982T3 (da) * | 2003-06-27 | 2013-01-28 | Astellas Pharma Inc | Terapeutisk middel til blødt væv-sarcom |
EP1670514B1 (de) | 2003-09-25 | 2010-06-23 | Astellas Pharma Inc. | Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer |
US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
-
2004
- 2004-09-24 EP EP04773539A patent/EP1670514B1/de active Active
- 2004-09-24 CA CA002540108A patent/CA2540108A1/en not_active Abandoned
- 2004-09-24 PL PL10163527T patent/PL2263694T3/pl unknown
- 2004-09-24 ES ES04773539T patent/ES2344899T3/es active Active
- 2004-09-24 DE DE602004027824T patent/DE602004027824D1/de active Active
- 2004-09-24 WO PCT/JP2004/014451 patent/WO2005030239A2/en active Application Filing
- 2004-09-24 EP EP10163527.4A patent/EP2263694B1/de active Active
- 2004-09-24 JP JP2006515402A patent/JP4779971B2/ja active Active
- 2004-09-24 PL PL04773539T patent/PL1670514T3/pl unknown
- 2004-09-24 AT AT04773539T patent/ATE471740T1/de active
- 2004-09-24 SI SI200432064T patent/SI2263694T1/sl unknown
- 2004-09-24 ES ES10163527T patent/ES2425083T3/es active Active
- 2004-09-24 DK DK10163527.4T patent/DK2263694T3/da active
- 2004-09-24 US US10/948,288 patent/US7314862B2/en active Active
- 2004-09-24 PT PT101635274T patent/PT2263694E/pt unknown
- 2004-09-24 MX MXPA06003222A patent/MXPA06003222A/es active IP Right Grant
-
2013
- 2013-09-09 CY CY20131100771T patent/CY1114359T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PL1670514T3 (pl) | 2010-11-30 |
WO2005030239A3 (en) | 2005-07-28 |
PT2263694E (pt) | 2013-08-27 |
ATE471740T1 (de) | 2010-07-15 |
MXPA06003222A (es) | 2006-05-22 |
ES2344899T3 (es) | 2010-09-09 |
JP2007506647A (ja) | 2007-03-22 |
DK2263694T3 (da) | 2013-08-26 |
ES2425083T3 (es) | 2013-10-11 |
SI2263694T1 (sl) | 2013-09-30 |
PL2263694T3 (pl) | 2013-11-29 |
EP2263694A1 (de) | 2010-12-22 |
EP1670514A2 (de) | 2006-06-21 |
US7314862B2 (en) | 2008-01-01 |
EP1670514B1 (de) | 2010-06-23 |
US20050070467A1 (en) | 2005-03-31 |
CA2540108A1 (en) | 2005-04-07 |
JP4779971B2 (ja) | 2011-09-28 |
WO2005030239A2 (en) | 2005-04-07 |
EP2263694B1 (de) | 2013-06-12 |
CY1114359T1 (el) | 2016-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004027824D1 (de) | Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer | |
TW200801006A (en) | Fused bicyclic mTOR inhibitors | |
TW200738725A (en) | Unsaturated mTOR inhibitors | |
ECSP055809A (es) | Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4 | |
MY148688A (en) | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors | |
EA200970932A1 (ru) | Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа | |
DE50311898D1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
EA200500859A1 (ru) | Хинолинилпирролопиразолы | |
UA84712C2 (en) | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors | |
IL189694A0 (en) | Biphenyl derivatives and their use in treating hepatitis c | |
BR0309343A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
TW200407326A (en) | Pyrimido compounds having antiproliferative activity | |
RS17004A (sr) | Alkin-arilski inhibitori fosfodiesteraze-4 | |
EA200970935A1 (ru) | Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа | |
HRP20030831B1 (en) | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases | |
DE602004025698D1 (de) | PYRIDINOi1,2-A PYRIMIDIN-4-ONVERBINDUNGEN ALS MITTEL GEGEN KREBS | |
TW200504012A (en) | Ethynylproline derivatives | |
CY1109732T1 (el) | Χρησις παραγωγων βενζο-συνενωμενου ετεροκυκλο σουλφαμιδιου δια την θεραπειαν πονου | |
BR0309342A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
TW200519111A (en) | N3-substituted imidazopyridine C-KIT inhibitors | |
PE20030061A1 (es) | 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4 | |
MXPA05004697A (es) | Soluciones farmaceuticas que comprenden un compuesto modafinil y uso para la fabricacion de un medicamento para tratar diferentes enfermedades. | |
CY1110130T1 (el) | Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α. | |
UA96304C2 (en) | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | |
GEP20094854B (en) | Compounds for treating diseases of impaired gastric motility |